Molecular Partners AG Logo

Molecular Partners AG

Pioneering DARPin protein drugs for complex diseases in oncology and virology.

MOLN | SW

Overview

Corporate Details

ISIN(s):
CH0256379097 (+1 more)
LEI:
875500AXMLDAZ4D21744
Country:
Switzerland
Address:
Wagistrasse 14, 8952 Schlieren
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Molecular Partners AG is a clinical-stage biopharmaceutical company that pioneers the design and development of DARPin therapeutics, a novel class of custom-built protein drugs. The company leverages its proprietary platform to create potent and specific therapies engineered to address complex medical challenges, particularly in oncology and virology, that other drug modalities cannot readily treat. Molecular Partners develops its pipeline of innovative therapeutic candidates independently and in collaboration with global partners to deliver new treatments for patients with serious diseases.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-07-07 07:25
Share Issue/Capital Change
Molecular Partners AG: Molecular Partners Successfully Completes the Launch of …
English 17.3 KB
2020-04-19 23:15
Regulatory Filings
Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi…
English 12.0 KB

Automate Your Workflow. Get a real-time feed of all Molecular Partners AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Molecular Partners AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Molecular Partners AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-09 N/A Executive member Sell None 47,784.80 CHF
2024-09-09 N/A Executive member Sell None 13,822.40 CHF
2024-04-02 N/A Executive member Sell None 243,000.00 CHF
2023-11-01 N/A Executive member Buy None 31,760.55 CHF
2022-02-15 N/A Executive member Sell None 2,410,500.00 CHF
2022-02-15 N/A Executive member Sell None 1,607,000.00 CHF

Peer Companies

Vaxcyte, Inc. Logo
A clinical-stage company developing broad-spectrum vaccines for bacterial infectious diseases.
United States of America
PCVX
VENTURE LIFE GROUP PLC Logo
Develops, manufactures, and distributes consumer self-care products and medical devices globally.
United Kingdom
VLG
Ventyx Biosciences, Inc. Logo
Clinical-stage biopharma developing oral therapies for autoimmune, inflammatory & neuro diseases.
United States of America
VTYX
Verastem, Inc. Logo
Develops cancer medicines targeting the RAS/MAPK pathway, with an approved therapy for ovarian cancer.
United States of America
VSTM
Vericel Corp Logo
Develops autologous cell therapies for sports medicine and severe burn care markets.
United States of America
VCEL
Verona Pharma plc Logo
Develops innovative therapies for chronic respiratory diseases like COPD and asthma.
United States of America
VRNA
Verrica Pharmaceuticals Inc. Logo
Develops topical therapies for skin diseases like molluscum contagiosum and common warts.
United States of America
VRCA
VERTEX PHARMACEUTICALS INC / MA Logo
Develops transformative medicines for serious diseases, specializing in cystic fibrosis.
United States of America
VRTX
VERU INC. Logo
Biopharma firm developing drugs for cardiometabolic and inflammatory diseases.
United States of America
VERU
Vetoquinol SA Logo
Develops and markets veterinary drugs and products for companion animals and livestock worldwide.
France
VETO

Talk to a Data Expert

Have a question? We'll get back to you promptly.